anti-mutcalr/anti-cd3 bispecific antibody inca035784
Generic: Anti-mutCALR/Anti-CD3 Bispecific Antibody INCA035784
anti-mutcalr/anti-cd3 bispecific antibody inca035784: 1 clinical trial tracked.
anti-mutcalr/anti-cd3 bispecific antibody inca035784 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-mutcalr/anti-cd3 bispecific antibody inca035784, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Interventionalopen120 targetStarted 2025-10Completion 2029-1226 sites · Australia, Belgium, Germany, Italy…Incyte Corporation